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Abstract
Background: Aquaporins (AQPs) are transmembrane water channels that facilitate
osmotically-driven transmembrane water flux. AQP1 is abundantly expressed in vascular
endothelium, where it functions in endothelial cell migration, wound healing, and cell
volume regulation in response to mechanical stimuli. AQP1 protein abundance is
enhanced in cultured human umbilical vein endothelial cells (HUVECs) in response to
fluid shear stress. Statins, a pharmacological class of HMG-CoA reductase inhibitors,
suppress the early development of vein graft intimal hyperplasia by improving
endothelial cell function, most likely by affecting endothelial response to arterial shear
stress. Statins may also differentially regulate the expression of specific AQPs by altering
their abundance and/or subcellular localization. Therefore, it is hypothesized that AQP1
may function as a component of the mechanosensory complex in endothelial cells and
therefore is subject to shear stress-induced gene regulation and modulation of expression
by statins.
Methods: HUVECs were cultured in microfluidic chambers under static (0 dynes/cm2)
and venous fluid shear stress (6 dynes/cm2) in the presence or absence of 5 µM
Pravastatin™. Fluorescent immunocytochemistry was used to detect AQP1 protein
expression. Images were captured using confocal laser scanning microscopy. Mean
fluorescent intensity (in arbitrary units) was determined using ImageJ software and
normalized to control conditions (time zero, static culture with no Pravastatin™).
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Twenty-five to thirty cells from two independent experiments were analyzed for each
experimental condition.
Results: AQP1 expression increased 1.4-fold (p<0.05) after 24 hours, and 1.5-fold
(p<0.05) after 48 hours in cells cultured under venous fluid shear stress as compared to
the control. This shear stress-induced expression was blocked by incubation with
Pravastatin™ and reduced by 27% (p<0.05; control vs. venous shear stress with
Pravastatin™). Pravastatin™ had no effect on AQP1 expression in static cultures (p>0.05
vs. control). These data indicate that Pravastatin™ suppresses shear stress dependent
induction of AQP1 in cultured HUVECs.
Conclusions: Results show that the shear stress-dependent induction of AQP1 protein
expression is suppressed by Pravastatin™. Results further demonstrate a potential
function of statin drugs in regulating the expression of AQPs that is both independent of
their cholesterol-lowering function and related to the regulation of AQP1 in vascular
endothelial cells.
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Chapter 1: Literature Review
1.1 The Role of Water in Human Physiology
Water (H 2 O) is an essential constituent of life. Water is a small tetrahedral shaped
molecule with two hydrogen atoms, one oxygen atom, and four valence electrons around
oxygen. The electronegative properties of the oxygen atom and the four valence electrons
around oxygen lend to the polar nature of H 2 O. This electronegative differential between
the more negative oxygen atom of the molecule and the two more positive hydrogen
atoms creates a permanent polar dipole that results in a partial negative charge on the
oxygen atom and a shared partial positive charge on the two hydrogen atoms. The polar
properties of water allow for water to serve as a universal solvent for polar and charged
molecules. This polar nature leads to the distinct electrostatic, cohesive, and adhesive
properties of H 2 O (36). As a universal solvent for polar and charge molecules, H 2 O is the
fundamental constituent of the various fluid filled components of the human body. Water
makes up approximately 60%-90% of human body weight and is an essential component
of normal cellular function, chemical and metabolic reactions, transport of nutrients,
thermoregulation of body temperature, and the elimination of waste from the body (50).
Given these chemical properties, H 2 O plays a fundamental role in biological
systems as a universal solvent. The polarity of the H 2 O molecule provides an
environment in which a large number of solutes are readily soluble in H 2 O. These solutes
include salts and other electrically charged or polar compounds. Water serves an
additional thermodynamic role in the solubility of molecules that are not polar or
electrically charged. In this instance, H 2 O forms a unique hydration shell that surrounds
the “dissolved” solute and effectively increases the entropy of the cellular system (36).
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Combined, the diverse capabilities of H 2 O as a solvent for polar and nonpolar molecules
provide the foundational environment for the necessary biochemical and metabolic
reactions that are present at the foundation of cellular and organismal health and function.

1.2 Osmolarity and Water Regulation at the Organismal and Cellular Level
Given the necessity of H 2 O and hydration in human physiology, it is important to
understand how H 2 O balance and homeostasis in the human body are managed. The
fundamental principle of fluid balance surrounds managing the sensitive osmolarity of
the intracellular and extracellular fluids. Osmolarity is a measure of the concentration of
the fluid compartments of the human body expressed as a total number of solute particles
per liter of solution (48). Osmoregulation is a vital process that regulates osmolarity and
osmotic pressure in a cell by means of regulating the composition and concentration of
intracellular and extracellular fluids (2).
At the organismal level in human physiology, osmoregulation is achieved through
integrated mechanisms involving the hypothalamus, pituitary gland, and the kidneys (44).
Circumventricular organs (CVOs) located in the hypothalamus and existing outside of the
blood-brain barrier contain specialized cells called osmoreceptors that respond to changes
in blood osmolarity. The osmoreceptors that are located specifically in the organum
vasculosum of the lamina terminalis in the brain send neural projections to the supraoptic
nucleus of the hypothalamus that promotes the release of vasopressin (also known as
anti-diuretic hormone) from the posterior pituitary. This process ultimately targets the
kidneys to adjust H 2 O reabsorption and excretion to compensate for increases or
decreases in osmolarity of the extracellular fluid (11). As a result, H 2 O balance at the
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organismal level is controlled through water retention and urine excretion from the
kidneys.
At the cellular level in human physiology, H 2 O is distributed between three fluidfilled compartments in the body: the intracellular fluid, the interstitial fluid, and the blood
plasma (48). Water balance between the intracellular and extracellular compartments is
mediated through three fundamental mechanisms. The first is osmosis, a slow and nonselective mechanism driven by osmotic gradients. The second is solute-coupled cotransport, a mechanism by which water essentially “hitches a ride” with another solute in
a co-transport mechanism. For example, H 2 O can enter a cell via this mechanism by
means of the sodium/glucose co-transporter through which sodium and glucose are cotransported into the cell with a “hitch-hiking” H 2 O molecule (7). The third mechanism is
one by which H 2 O balance is regulated at the cellular level through channel proteins in
the membrane that form pores in the cellular membrane that allow for the passive,
regulated, and selective route for the transmembrane flux of H 2 O molecules. These
channel proteins are called aquaporins (AQPs) (1, 46) (Fig. 1).

Page |4

Figure 1. Mechanisms of transmembrane water movement
Water can move across the cellular membrane by three mechanisms. The first is osmosis
in which water moves across a cellular membrane in response to an osmotic gradient. The
second is the solute-coupled co-transportation of water, along with other solutes such as in
the Na+/Glucose membrane transport protein. The third is through water-specific channel
proteins called aquaporins.

1.3 Aquaporins
While osmosis and solute-coupled water transport are effective mechanisms for
transporting water in and out of cells, these processes are limited. Osmosis is slow, nonselective for water, and is driven only by osmotic gradients. Solute-coupled transport
requires a solute to function, and it is a non-direct and non-selective mechanism for water
transport. These limitations are compensated for with AQPs. Aquaporins are regulated
and selective proteins that provide a route through the cell membrane for osmoticallydriven transmembrane water flux. In the compartmentalized system of a cell, a
selectively-permeable membrane exists that is composed of a bilayer of phospholipids.
This phospholipid bilayer has externally and internally facing phosphate groups that are
hydrophilic (“water-loving”) and interact with the polar H 2 O component of the
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extracellular and intracellular fluid. The parts of the bilayer that are inside the membrane
are composed of long-chain carbohydrate lipids that are non-polar and
lipophilic/hydrophobic (“lipid-loving”/ “water-fearing”). The non-polar nature of these
membrane lipids significantly hinders the passive and spontaneous migration of H 2 O
through the membrane. The solution to this issue is the presence of membrane spanning
water channels called AQPs that create a functional pore in the cellular membrane by
which H 2 O can pass through the membrane.
Aquaporins were discovered by experimental serendipity. In 1991, Dr. Peter Agre
and colleagues were investigating the group of Rh antigens expressed on the surface of
red blood cells. During this investigation, the group consistently observed an unusual
protein band on gel electrophoresis experiments. At first the researchers assumed this
band of 28 kilodaltons (kDa) size was a contaminant in early protein preparations (45).
To the group’s surprise, this unusual band was an unidentified protein that is highly
abundant in human red blood cells and the epithelial membranes of the proximal renal
tubules in the kidney (46). While the actual function of this protein was unknown to Agre
and his colleagues, they hypothesized that this protein might be responsible for H 2 O
transport across the cellular membrane due to the high permeability of H 2 O in red blood
cells and in the cells of proximal renal tubules.
With this hypothesis in mind, Agre and colleagues used oocytes from the African
clawed frog, Xenopus laevis, and expressed this unknown protein in these cells by
microinjecting in vitro transcribed CHIP28 RNA into the oocytes. Since these cells
normally have a low cellular permeability to H 2 O, the researchers were interested in
investigating if the exogenous expression of this proposed water channel in the oocytes
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would alter the H 2 O permeability of these cells. As expected from the group’s
hypothesis, the expression of this 28 kDa protein in the oocytes dramatically increased
the water permeability of these cells (46). Agre later discovered that this protein existed
in two forms: a non-glycosylated form at 28 kDa in size and a glycosylated form at 60
kDa (46). In 2003, Agre was awarded the Nobel Prize in Chemistry for the discovery of
CHIP28 (channel-like integral protein of 28-kDa) (46), today referred to as Aquaporin 1
(AQP1). Since the discovery of AQP1, other researchers have identified 13 human AQP
proteins (AQP0-AQP12) (13, 19, 20, 54).

1.4 Structure and Function of Aquaporins
AQPs belong to the major intrinsic proteins (MIP) family of transmembrane
proteins (1). From high-resolution x-ray crystal diffraction, it has been determined that
AQPs exist as a tetramer of four AQP protein monomers. Four AQP monomers assume a
quaternary protein structure in the cellular membrane (4). Each monomer is composed of
six membrane-spanning helical domains with two intra- and extracellular loops that form
the functional water pore of the aquaporin (54). All AQPs, with the exception of AQP7, 11, and -12, contain a conserved three amino acid domain of Asparagine (N), Proline (P),
and Alanine (A) within these loops (22, 56) (Fig. 2). In AQP7, the first intracellular loop
is an AAA motif and the second extracellular loop is a NP and Serine (S) motif (56). In
AQP11, the first intracellular loop is NP and Cysteine (C), and in AQP12 the first
intracellular loop is NP and Threonine (T) (13, 20).

Page |7

Figure 2. Aquaporin 1 structure
Structure of AQP1 in the cellular membrane. Alpha helices 1-6 represent transmembrane
domains. The two NPA motifs in the first intracellular loop and third extracellular loop
fold into the membrane to form the functional water pore.

The narrow pore region of the AQP is formed through the interaction of the amino
acids located within the two intermembrane loops and the transmembrane domains (His
182, Arg 197, Cys 191, Phe 58). These interactions form a pore size of 2.8-Å (52) (Fig.
3).
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Figure 3. Three-dimensional structure of AQP1 monomer and tetramer.
Pictured is the three-dimensional representation of a single AQP1 monomer as viewed
from the side (A) and the AQP tetramer complex as viewed from the top down (B). Four
visible water pores can be viewed in the tetrameric complex from this top down view.

Structural analysis and simulations of the molecular dynamics of these water
channel proteins have determined that H 2 O moves through these channels in a single-file
manner by which only one H 2 O molecule is transported through the channel at a time.
The H 2 O molecule travels through the channel by electrostatically and sterically
interacting with the intermembrane amino-acid residues of the tetramer and by forming
and breaking short-lasting hydrogen bonds between the H 2 O molecules and the amino
acid residues of the channel (51).
Through the unique structure and function of AQPs, these channel proteins serve
to facilitate osmotically driven transmembrane H 2 O flux (35). Cells that express AQPs in
their cellular membranes have on average a ~5 to ~50-fold increase in osmotic H 2 O
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permeability as compared to cells that do not express AQPs in their cellular membranes
(30). The 13 mammalian AQPs are expressed in diverse cells and tissues throughout the
human body. The cells that express AQPs in these cells and tissues have a high capacity
for H 2 O permeation. Listed below in Table 1 is the tissue distribution of the 13 AQPs
(13, 19, 20, 54).
Table 1: Location of aquaporin isoforms in the human body
Aquaporin
Isoform
0
1
2
3
4
5
6
7
8
9
10
11
12

Location in the Human Body
Lens
Blood Vessels, Kidney Proximal Tubules, Eye, Red Blood Cells, and
Ear
Kidney Collecting Duct (principal cells)
Kidney Collecting Duct (principal cells), Epidermis, Urinary,
Respiratory, and Digestive Tracts
Brain Astrocytes, Eye, Ear, Skeletal Muscle, Stomach Parietal Cells,
and Kidney Collecting Ducts
Salivary, Lacrimal, and Sweat Glands. Lungs.
Intracellular Vesicles in the Kidney Collecting Ducts
Adipocytes, Testis, and Kidney
Kidney, Testis, and Liver
Liver and Leukocytes
Intestine
Adipocyte, Kidney, Liver
Pancreas

Of the 13 isoforms of AQPs, AQP1 is specifically expressed in microvascular
endothelium located in areas outside the brain such as in the microvessels of the kidney,
lung and airways, secretory glands, skeletal muscle, pleura, and peritoneum (6, 8, 10, 14,
16, 37). In the vascular endothelium, AQP1 functions to facilitate osmotically-driven
transmembrane H 2 O flux, wound healing and angiogenesis, as well as in the
pathophysiology of fibrosis in selective disease states (18, 53).
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1.5 Coronary Artery Disease: Clinical Presentation, Disease Pathophysiology, and
Treatment.
Coronary Artery Disease (CAD) is the leading cause of death in American men
and women. Indeed, 1 in 5 deaths in American men and women result from CAD (26).
On a global scale, it is anticipated that the mortality caused by CAD will increase to
around 23.4 million a year by the year 2030 (49). CAD ultimately manifests itself after at
least one of the epicardial arteries of the heart becomes congested with a buildup of
cholesterol and lipid plaques (Fig. 4).
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Figure 4. Gross anatomy of the human heart.
Gross anatomy of the human heart outlining major anatomical structures and vessels. The
labels underlined in red indicate the locations of the coronary arteries. These are the vessels
susceptible to CAD.

These cholesterol and lipid plaques lead to vascular ischemia (reduced blood
flow) and a condition called atherosclerosis. Atherosclerosis results from a buildup of
cholesterol and fat that together harden and narrow the diameter of coronary arteries (Fig.
5).

P a g e | 12

Figure 5. Vessel occlusion from atherosclerotic plaque buildup.
As fatty lipid plaques begin to accumulate in vessels, the diameters of these vessels begin
to decrease as the disease progresses from Stage 1, pictured above, to the final Stage 4 at
which there is near complete blockage of the artery.
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This narrowing limits the flow of oxygen-rich blood to the myocardial tissue of
the heart, and as a result this narrowing leads to the development of CAD (38, 39). Were
these plaques to rupture inside the vessels, the rupture would promote an inflammatory
response in which platelets, naturally found in the blood, would adhere to the site of
damage on the endothelial wall of the vessel. If these platelets adhere and conglomerate
so densely that they occlude the vessel, they can result in a blood clot or even a
myocardial infarction (heart attack) (40). Considering in full the high mortality resulting
from CAD, the risks associated with severe CAD, and the direct role of endothelial
dysfunction in the development of CAD, it is important to understand how the
endothelium functions in order possibly to prevent the onset and manifestation of CAD.
The most common interventional approach to correct vessel occlusion from the
development of atherosclerosis and CAD is a surgical procedure known as coronary
artery bypass graft (CABG) surgery. This procedure involves first the removal of either
the patient’s saphenous vein (HSV) from the leg or the internal mammary artery (IMA)
and then the grafting of one of these vessels onto the heart to fulfill the role of an
occluded coronary artery. The HSV graft is used primarily for blockages of the anterior
descending coronary arteries, while the IMA graft is used for posterior coronary artery
congestion (Fig. 4). CABG involves the bypassing of blood flow around the sections of a
coronary artery congested with atherosclerotic plaques. The effect is that normal blood
and oxygen flow is returned to the muscle of the heart (myocardium) (33) (Fig. 6).
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Figure 6. Coronary artery bypass graft procedure.
CABG surgery involves the use of either the human saphenous vein or internal mammary
artery to redirect blood flow from the aorta to the blocked coronary artery. This figure
shows a vein or artery graft redirecting blood flow from the aorta to the left anterior
intraventricular artery.

While both vessel grafts are effective in bypassing blood flow around the
congested coronary artery, the long-term effectiveness or patency of these two grafts are
markedly different. It is understood that the HSV grafts have clinically worse outcomes
over the long term in comparison to the IMA grafts. Within ten years following
operation, HSV graft patency is 61%, while IMA graft patency is 85% (12). Additionally,
HSV grafts have high rates of initial failure up to 25% within twelve to eighteen months
following surgery (15, 27). With graft failure, a secondary procedure is required to
bypass the vessels damaged by the failed HSV graft. The reasons for the failure of these
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grafts is unknown; researchers hypothesize that differences in the venous and arterial
environment may cause aberrant regulation of specific gene expression patterns that
result in blood vessel dysfunction (29).
Considering that the endothelial cell layer is the first line of physical contact
between the vasculature and the flow of blood, the endothelial cell layer provides an
important role in maintaining overall vessel health and normal physiology (47). Disease
pathophysiology of the vasculature, such as atherosclerosis and intimal hyperplasia (IH),
stems directly from damage and disruption to this endothelial cell layer (43). Intimal
hyperplasia is a disease caused by aberrant thickening of the sub-endothelial intimal layer
of a blood vessel (32). Changes in vascular shear stress are suggested to be one of the
early causes of downstream vessel dysfunction and IH following CABG procedures (23).
Given the significant role of the endothelium in the presentation of normal and
abnormal physiology of the vasculature and overall cardiovascular system, it is important
to understand the role of endothelial function and dysfunction in cardiovascular disease.

1.6 Fluid Shear Stress and Vascular Endothelium
Under normal physiological conditions, the vascular endothelium is constantly
exposed to a variety of physical stressors called hemodynamic forces. The most
commonly described hemodynamic forces are circumferential hoop stress and shear
stress. Circumferential hoop stress is caused by the circumferential distension of a vessel
wall by changes in blood pressure (28). Shear stress (expressed in units of dynes/cm2),
the focus of this thesis, is the force per unit area created when a tangential force such as
blood (or any fluid) flows parallel across a surface like the vascular endothelium.
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Depending on the viscosity of the fluid, the length of chamber or vessel, the change in
pressure across chamber or vessel, and the radius of the chamber or vessel, it is possible
to calculate the shear stress applied to the wall of the chamber or vessel (55) (Equation
1).
𝝉𝝉 = 𝟒𝟒𝟒𝟒 ∙

𝑸𝑸
𝝅𝝅𝒓𝒓𝟑𝟑

𝝉𝝉 = 𝑆𝑆ℎ𝑒𝑒𝑒𝑒𝑒𝑒 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆

𝜼𝜼 = 𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉

𝑸𝑸 = 𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹 = 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑒𝑒 ′ 𝑠𝑠 𝐿𝐿𝐿𝐿𝐿𝐿 =

ΔP ∙ 𝜋𝜋 ∙ 𝑟𝑟 4
8 ∙ 𝜂𝜂 ∙ 𝑙𝑙

𝚫𝚫𝑷𝑷 = 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 𝑇𝑇ℎ𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟ℎ 𝑎𝑎 𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉
𝒍𝒍 = 𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿ℎ 𝑜𝑜𝑜𝑜 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉
𝒓𝒓 = 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅

Equation 1. Equation for calculating shear stress in a closed vessel

Shear stress is exerted on vascular endothelium wherever there is blood flow (5)
(Fig. 7). Shear stress on the wall of blood vessels and specifically on the vascular
endothelium cannot be measured directly in vivo. However, shear stress can be calculated
with the knowledge of blood’s viscosity near the region of interest. While this might
seem straightforward simply to measure the blood viscosity at the region of interest and
use this information to calculate in vivo shear stress, this can be difficult due to a process
called plasma skimming. During plasma skimming, the number of red blood cells
interacting with and exerting a force upon wall of the vessel is inconsistent due to the
relatively low level of red blood cells located directly adjacent to the vessel wall. In
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addition, the diameter of a blood vessel varies significantly over the period of a single
heartbeat. This provides additional difficulty in calculating blood viscosity and shear
stress in vivo. It is estimated that shear stress ranges across the entire human vasculature
from levels less than 10 dynes/cm2 to levels upwards of 70 dynes/cm2 (41).

Figure 7. Fluid shear stress in blood vessels.
As blood flows through a vessel, shear stress is applied in the same direction of blood flow.
Shear stress is the mechanical stress of blood flow across the endothelial cell layer that
lines the inside of blood vessels.

1.7 Fluid Shear Stress Regulation of AQPs
As blood flows across the endothelial cell layer, the cell layer responds to this
stress by regulating blood vessel physiology (47). The endothelial cell layer converts the
mechanical stimuli of the shear stress into intracellular signaling pathways that can have
effects on overall cellular function, proliferation, apoptosis, migration, permeability,
remodeling, and gene expression (25).
While fluid shear stress in the context of this investigation is described as blood
flow across endothelial cells, fluid shear stress exists anywhere there is fluid flowing
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across a layer of cells such as in the epithelial layers of fluid filled structures. Such an
environment exists in the proximal tubule of the kidney. As blood filtrate flows through
the proximal tubule, fluid shear stress is exerted on the epithelial lining and results in
modifications of downstream gene expression patterns. Of relevance is the regulation of
AQP1 by fluid shear stress in these structures. It has been demonstrated by Pohl et al. that
increases in fluid shear stress in vitro and in vivo upregulate the expression of AQP1 in
the proximal tubular epithelial cells (42). These investigators demonstrated a significant
increase in AQP1 expression under fluid flow, suggesting a shear stress dependent
mechanism for regulating AQP1 expression.
In a separate study by Mun et al., this same regulation of AQP1 by shear stress
was again demonstrated in vascular endothelial cells, suggesting a cell type-independent
regulation of AQP1 by fluid shear stress. Increasing levels of shear stress from static
conditions to flow conditions were shown to induce the expression of AQP1 in
endothelial cells (34). It is hypothesized that this mechanically-driven induction of
AQP1 under increasing shear stress serves as an early environmental sensor or biomarker
as fluid shear stress increases from a venous to arterial environment.

1.8 Statins and AQPs
Statins belong to the class of drugs called HMG-CoA reductase inhibitors. These
drugs function as cholesterol-lowering agents. They inhibit the rate-limiting step in the
biochemical synthesis of cholesterol by direct inhibition of the enzyme HMG-CoA
reductase (17). An essential sterol in the human body, cholesterol in normal
concentrations serves in a wide variety of physiological roles including maintaining cell
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membrane fluidity. However, increased amounts of low-density lipoprotein (LDL)
cholesterol are detrimental to overall cardiovascular health. Increased plasma levels of
LDL cholesterol can lead to a buildup of atherosclerotic plaques in blood vessels that
directly affects the normal function of the vascular endothelium. These atherosclerotic
plaques can cause damage to the overall vasculature by means of vascular inflammation,
occlusion, and vessel wall thickening from IH (31). These effects of increased LDL
cholesterol are the reasons why statins are commonly prescribed to those individuals
suffering from CAD and are undergoing CABG procedures. This prescription is to
prevent the accumulation of atherosclerotic plaques in newly implanted grafts as well as
to prevent the regression of the vessel into significant coronary atherosclerosis (9).
Statins function as cardioprotective agents that reduce the risk of CAD and other
cardiovascular diseases resulting from excessive LDL cholesterol. The current
understanding of the cholesterol-independent cardioprotective effect of statins is that
statins reduce endothelial permeability and vascular inflammation through the inhibition
of Rho GTPases (3). These Rho GTPases function as molecular switches that regulate
signal transduction and gene expression in endothelial cells (9). Through reducing
endothelial permeability to immune cells such as leukocytes, statins reduce vascular
inflammation that can lead to downstream vascular disease.
It has been observed that statins demonstrate a regulatory effect on certain
members of the AQP family independent of their cholesterol-lowering effect. Statins
regulate the expression of AQP1, -8, and -9 in cardiomyocytes following ischemicreperfusion injury. Similar to the shear-stress induction of AQP1 in the proximal tubular
epithelial cells and in HUVECs, AQP1, -8, and -9 are upregulated in the cardiomyocytes
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after an ischemic event followed with reperfusion (24). This ischemia-reperfusion
triggered induction of AQP1, -8, and -9 is prevented with the pretreatment of these cells
with the hydrophilic statin, Simvastatin™. The effect of Simvastatin™ was effectively
counteracted by the addition of a protein-kinase A (PKA) inhibitor. These findings
suggest that simvastatin exerts a cholesterol- and tissue-independent function in
regulating AQPs through a PKA-dependent manner (24). This might additionally suggest
a cholesterol-independent target of statin drugs in regulating AQPs and specifically
AQP1 in tissue under flow conditions.

1.9 Hypothesis
The objective of this investigation is to investigate the role of the hydrophilic
statin Pravastatin™ on the regulation of AQP1 in vascular endothelial cells under static
and venous fluid shear stress conditions.
It is likely that the cardioprotective function of statin drugs is a result of the effect
that statins have in different cell types in regulating AQPs rather than exclusively on the
lowering of LDL cholesterol (24, 34, 42). Previous findings have demonstrated that
increases in shear stress from static to venous to arterial levels of shear stress can increase
the expression of endothelial AQP1 (34). Given this understanding that AQP1 is
upregulated in response to increasing levels of shear stress, and given that it is the
increase in shear stress between a venous and an arterial environment that is proposed to
be one of the reasons for CABG vein graft failure, it is possible that AQP1 might serve as
a target for drug therapy focused on improving graft performance. In addition to the
hypothesis that an increase in shear stress is a potential cause of CABG vein graft failure,
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it is also hypothesized that increasing vascular permeability and inflammation can lead to
graft failure. Aquaporin 1-null humans had significantly reduced vascular permeability in
the vessels of the lungs as compared to normal humans (21). If it is proposed that
reducing vascular permeability is a solution to preventing vein graft failure, then the
absence or reduction of AQP1 in the vasculature would be optimal. A drug that could
reduce this shear-stress dependent induction of AQP1 or even block its expression would
function to mitigate the physiological stress that is caused by transplanting a vein graft to
an arterial role in the heart.
Therefore, it is proposed that the reduction in vascular endothelial permeability
caused by statin drugs functions through the regulation of AQP1 expression and
subcellular localization in HUVECs rather than exclusively through a cholesterollowering mechanism. This suggests that statins might serve a role in the regulation of
AQP1 in the vascular endothelium that supersedes the cholesterol-lowering purpose of
statins and provides a cardioprotective benefit of reduced endothelial permeability.
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Chapter 2:
Pravastatin™ Suppresses Venous Shear Stress Dependent
Induction of Aquaporin 1 Protein Expression in Human
Umbilical Vein Endothelial Cells in vitro.
2.1 Abstract
Background: Aquaporins (AQPs) are transmembrane water channels that facilitate
osmotically-driven transmembrane water flux. AQP1 is abundantly expressed in vascular
endothelium, where it functions in endothelial cell migration, wound healing, and cell
volume regulation in response to mechanical stimuli. AQP1 protein abundance is
enhanced in cultured human umbilical vein endothelial cells (HUVECs) in response to
fluid shear stress. Statins, a pharmacological class of HMG-CoA reductase inhibitors,
suppress the early development of vein graft intimal hyperplasia by improving
endothelial cell function, most likely by affecting endothelial response to arterial shear
stress. Statins may also differentially regulate the expression of specific AQPs by altering
their abundance and/or subcellular localization. Therefore, it is hypothesized that AQP1
may function as a component of the mechanosensory complex in endothelial cells and
therefore is subject to shear stress-induced gene regulation and modulation of expression
by statins.
Methods: HUVECs were cultured in microfluidic chambers under static (0 dynes/cm2)
and venous fluid shear stress (6 dynes/cm2) in the presence or absence of 5 µM
Pravastatin™. Fluorescent immunocytochemistry was used to detect AQP1 protein
expression. Images were captured using confocal laser scanning microscopy. Mean
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fluorescent intensity (in arbitrary units) was determined using ImageJ software and
normalized to control conditions (time zero, static culture with no Pravastatin™).
Twenty-five to thirty cells from two independent experiments were analyzed for each
experimental condition.
Results: AQP1 expression increased 1.4-fold (p<0.05) after 24 hours, and 1.5-fold
(p<0.05) after 48 hours in cells cultured under venous fluid shear stress as compared to
the control. This shear stress-induced expression was blocked by incubation with
Pravastatin™ and reduced by 27% (p<0.05; control vs. venous shear stress with
Pravastatin™). Pravastatin™ had no effect on AQP1 expression in static cultures (p>0.05
vs. control). These data indicate that Pravastatin™ suppresses shear stress dependent
induction of AQP1 in cultured HUVECs.
Conclusions: Results show that the shear stress-dependent induction of AQP1 protein
expression is suppressed by Pravastatin™. Results further demonstrate a potential
function of statin drugs in regulating the expression of AQPs that is both independent of
their cholesterol-lowering function and related to the regulation of AQP1 in vascular
endothelial cells.
Funding: This research was funded by the Schuellein Chair in the Biological Sciences
(CMK), the University Honors Program of the University of Dayton (RJC), and a 2015
American Physiological Society Summer Undergraduate Research Fellowship Award to
RJC.
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2.2 Introduction
Aquaporins (AQPs) belong to the major intrinsic family of transmembrane proteins
and function to facilitate osmotically-driven transmembrane water flux (1, 29). Of the 13
human AQPs, Aquaporin 1 (AQP1) is abundantly expressed in the vascular endothelium
where it has been demonstrated to function in endothelial cell migration, wound healing,
and cell volume regulation in response to mechanical stimuli (9, 12, 17). As blood flows
across the vascular endothelium, the endothelial cell layer is exposed to a tangential
mechanical force called laminar fluid shear stress (7, 8). In response to this mechanical
stimulus, endothelial cells regulate whole blood vessel physiology (30). This response
involves the conversion of mechanical stress into downstream intracellular signaling
pathways that have an overall effect on regulating cellular function, proliferation,
apoptosis, migration, permeability, and remodeling as well as endothelial cell gene
expression (22).
Considering that the endothelium is the first line of physical contact between the
vasculature and the flow of blood, the endothelial cell layer serves an important function
in maintaining overall vessel health and normal physiology (30). Disease
pathophysiology of the vasculature, such as intimal hyperplasia (IH), stems directly from
damage and disruption to this endothelial cell layer (30). Given the significant role of the
endothelium in normal and abnormal physiology of the vasculature and overall
cardiovascular system, it is important to understand the role of endothelial cell function
and dysfunction in cardiovascular disease.
It is known that fluid shear stress regulates the expression of members of the AQP
family, specifically AQP1, in vitro and in vivo. Of the 13 isoforms of AQPs, AQP1 is
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specifically expressed in endothelium located outside the brain such as in the
microvessels of the kidney, lung and airways, secretory glands, skeletal muscle, pleura,
and peritoneum (9–11, 13, 26). In the proximal tubule of the kidney, an increase in fluid
shear stress upregulates the expression of AQP1 in proximal tubular epithelium and
affects the trafficking of AQP1 to the apical membrane of these epithelial cells (15). This
increase in expression and membrane localization induced by fluid shear stress suggests a
shear stress dependent mechanism for regulating AQP1 expression and intracellular
distribution. Similarly, in vitro, a change in the level of shear stress from static culture
conditions to flow conditions induced the expression of AQP1 in endothelial cells,
suggesting a cell-type independent regulation of AQP1 by changes in fluid shear stress
(24).
Statin drugs belong to the class of pharmaceuticals called HMG-CoA reductase
inhibitors that function as cholesterol-lowering drugs by inhibiting the rate-limiting step
in the biochemical synthesis of cholesterol (18). The statin class of drugs has been
proposed to have a cholesterol-lowering independent effect on the expression of varying
AQPs. Statins are known to regulate protein expression of AQP1, -8, and -9 in
cardiomyocytes following ischemic-reperfusion injury. AQP1, -8, and -9 are upregulated
in cardiomyocytes after an ischemic event followed with reperfusion (21). This ischemiareperfusion triggered induction of AQP1, -8, and -9 is prevented with the pretreatment of
the cardiomyocytes with the hydrophilic statin, Simvastatin™, resulting in inhibiting
cardiomyocyte swelling due to water influx. This Simvastatin™ prevented induction of
AQP1, -8, and -9 in cardiomyocytes was effectively counteracted by the addition of a
protein-kinase A (PKA) inhibitor, suggesting that statins might exert a cell-type

P a g e | 33

independent effect in regulating AQP expression (21). Aquaporins might serve as targets
of statins in various cell types under flow conditions.
The objective of this investigation is to determine the role of Pravastatin™, a
hydrophilic statin drug, on the regulation of AQP1 protein expression in human umbilical
vein endothelial cells (HUVECs) under static and venous fluid shear stress conditions in
vitro. It is suspected that the function of statin drugs independent of their cholesterollowering primary utility is a result of the effect that statins might have in endothelial
cells, specifically HUVECs, on the regulation of AQP1. It is therefore hypothesized that
the fluid flow induction of AQP1 observed in vitro (24) will be altered by administering
Pravastatin™ in an in vitro model of fluid shear stress in HUVECs.

2.3 Materials and Methods
Cell Culture of Human Umbilical Vein Endothelial Cells (HUVECs)
Human umbilical vein endothelial cells harvested from normal full-term umbilical
cord veins (Coriell Cell Repositories, Line WC00103) were cultured in complete cell
culture media (CCCM, Lonza CC-3156) and supplemented with EBM-2 Bulletkit (Lonza
CC-3162) and 7.5% Fetal Bovine Serum (GE Healthcare Life Sciences SH30071.03) in
cell culture flasks coated with 1% gelatin. HUVECs were incubated in a CO 2 Incubator at
37°C and 5% CO 2 (Barnstead International Model 490).

Exposing HUVECs to venous fluid shear stress and Pravastatin™
Human umbilical vein endothelial cells were seeded at 5 x 105 cells/ml (static
conditions) or at 2 x106 cells/ml (flow conditions) in 1% gelatin-coated microfluidic
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chambers (0.4 mm ibidi® µ-slides: ibidi 80601), and incubated at 37℃ and 5% CO 2 in
CCCM + Supplements for 24 hours prior to exposure to 5µM Pravastatin™ (EMDMillipore 524403) and/or to the application of “venous” fluid shear stress (6 dynes/cm2)
for 24 or 48 hours. Cells after the initial 24-hour incubation with no Pravastatin™ and no
shear stress were used as a “Static 0 Hr” control for the purpose of data standardization.
Shear stress was applied using the 913 Mityflex peristaltic pump. Complete cell
culture media + supplements with or without Pravastatin™ was placed in an Erlenmeyer
flask, and the bioreactor apparatus was setup as described in Chambers (4) in a sterile
Class II biosafety cabinet (Labconco Corporation 3620804). Temperature and CO 2 were
monitored using GasLab® 2.0 software on an external computer setup. Cells were
exposed to shear stress (6 dynes/cm2) for 24 and 48 hours. Complete cell culture media +
supplements (with or without Pravastatin™) was replaced after 24 hours of culture under
static and flow conditions.

Immunocytochemistry
Human umbilical vein endothelial cells seeded in microfluidic chambers were
washed with 1X Phosphate Buffered Saline (PBS) (pH 7.4) and then fixed with 4%
paraformaldehyde in PBS. Slides were blocked using 10% blocking serum [0.24 g
Bovine Serum Albumin (Sigma Aldrich A9418), 600 µL goat serum (Vector
Laboratories S-1000), 30 µL Tween-20 (Sigma P9416), and 5.3 mL of 1x PBS].
HUVECs were incubated at 4º C with 1:100 dilutions of primary antibody for AQP1
(Santa Cruz Biotechnology 32737), PECAM-1 (Santa Cruz Biotechnology 8306), or
BMPER (Santa Cruz Biotechnology 377502).
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Following primary antibody incubation, HUVECs were exposed to fluoresceinconjugated secondary antibodies at a 1:200 dilution in 1% blocking serum [(Goat AntiMouse IgM Antibody; Vector Laboratories FI-2020) (Goat Anti-Rabbit IgG Antibody;
Vector Laboratories FI-1000)]. HUVECs were then exposed to a 1:100 dilution of TexasRed Phalloiden (Life Technologies T7471) in 1% blocking serum to stain for F-actin, a
cytoskeletal protein in HUVECs. Cell nuclei were stained using TOPRO-3 (Life
Technologies T3605), a nuclear stain, diluted 1:500 in Vectashield fluorescent mounting
media (Vector Laboratories H-1000). Slides were stored in the dark at 4ºC.
Immunofluorescence was detected using an Olympus Fluoview 1000 Laser Scanning
Confocal Microscope, and images were taken of the HUVECs at 20x and 40x
magnification.

Statistical Analysis
Immunoreactivity of AQP1, BMPER, and PECAM mean fluorescent intensity
was quantified from twenty to thirty cells from each 20x magnification image using the
“Freehand Selection Tool” provided in ImageJ, and averages and standard error of the
means were calculated for graphical representation. A four-square grid was superimposed
on the images and cells were sampled from the top left and bottom right quadrants of the
images. Mean fluorescent intensity values were normalized to the Static 0 Hr and
compared between experiments. All experiments were repeated and relative normalized
values across replicates were compared for statistical replication. These mean fluorescent
intensity values +/- standard error of the mean were represented as arbitrary units (a.u.).
A blocking variable for experimental replicates was used to determine nonsignificant
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differences between experimental replicates (p>0.05). Conditions were compared using
an ANOVA with Tukey’s Honest Significant Difference post-hoc correction.
Significance was determined at p<0.05.

2.4 Results
Effect of Venous Fluid Shear Stress on HUVECs
Initial experiments were focused on understanding how a change in fluid shear
stress from static conditions to venous conditions might affect protein expression in
HUVECs in vitro. Specifically, the experiments were designed to examine how a change
in shear stress from a static environment to venous flow environment might affect the
expression of AQP1.
Venous fluid shear stress induced AQP1 protein expression 1.4-fold relative to
Static 0 Hour Control (Fig. 8, Panel F vs. Panel B), Static 24 Hours (Fig. 8, Panels E-H)
and Venous Flow 24 Hours (Fig. 8, Panels I-L; Fig. 9, A; Fig. 9, B; p<0.05). AQP1
expression was induced 1.5-Fold after 48 hours of venous flow relative to Static 0 Hour
Control (Fig. 8, Panel R vs. Panel B; Fig. 9, D; p<0.05). No significant difference in
AQP1 expression was observed between Venous Flow for 24 hours as compared to cells
cultured under Venous Flow for 48 hours (Fig. 8, Panel J vs. Panel R; p>0.05).
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Figure 8. Venous fluid shear stress induces AQP1 expression in HUVECs.
Immunocytochemistry images of AQP1 (Green), F-Actin (Red), and the cell nuclei (Blue)
acquired at 20x magnification of HUVECs cultured under static (A-H, M-P) and venous
fluid shear stress conditions (I-L, Q-T) for 0 (A-D), 24 (E-L), and 48 hours (M-T). The
direction of applied flow is from right to left. Scale Bar: 100 µm.
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Figure 9. AQP1 expression is induced by venous shear stress.
Mean fluorescent intensities (Arbitrary Units or A.U.) of AQP1 immunofluorescence (Fig.
8, Panels F, J, N, and R) normalized to Static 0 Hour Control (Fig. 8, Panel B) with standard
error of mean. Significant differences (*) were determined at p<0.05.

Platelet Endothelial Cell Adhesion Molecule 1 (PECAM-1) was used as a positive
marker for identifying non-differentiated endothelial cells (25). Relative to Static 0 Hour
Control, the PECAM-1 expression did not change under static or venous flow conditions
at 24 and 48 hours of culture indicating that shear stress has no effect on PECAM-1
expression, and indicates that the HUVECs maintained endothelial cell identity (Fig. 10,
Panels B, F, J, N, and R; Fig 11; p>0.05).
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Figure 10. PECAM-1 expression is not affected by shear stress.
Immunocytochemistry images of PECAM-1 (Green), F-Actin (Red), and the cell nuclei
(Blue) acquired at 20x magnification of HUVECs cultured under static (A-H, M-P) and
venous fluid shear stress conditions (I-L, Q-T) for 0 (A-D), 24 (E-L), and 48 hours (M-T).
The direction of applied flow is from right to left. Scale Bar: 100 µm.
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Figure 11. PECAM-1 expression is not affected by venous shear stress.
Mean fluorescent intensities (A.U.) (Fig. 10, Panels F, J, N, and R) normalized to Static 0
Hour Control (Fig. 10, Panel B) with standard error of mean. No significant differences
across conditions were observed (p>0.05).

Bone Morphogenetic Protein-Binding Endothelial Cell Precursor-Derived
Regulator (BMPER) a protein that has been shown to be up-regulated in endothelial cells
by Pravastatin™, was used as a positive control for the effect of Pravastatin™ in
HUVECs (16). Relative to Static 0 Hour Control, the BMPER expression remained
constant under static or venous flow conditions at 24 and 48 hours of culture (Fig. 12,
Panels B, F, J, N, and R; p>0.05).
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Figure 12. BMPER is not expressed in HUVECs cultured under static or venous shear
stress conditions.
Immunocytochemistry images of Pravastatin™ positive control BMPER (Green), F-Actin
(Red), and the cell nuclei (Blue) acquired at 20x magnification of HUVECs cultured under
static (A-H, M-P) and venous fluid shear stress conditions (I-L, Q-T) for 0 (A-D), 24 (EL), and 48 hours (M-T). The direction of applied flow is from right to left. Scale Bar: 100
µm.
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Effect of 5µM Pravastatin™ on Static Cultured HUVECs
Pravastatin™ in CCCM was added to static HUVEC cultures to assess the effect
of Pravastatin™ on HUVECs independent of venous fluid shear stress. These
experiments were performed to assess the effect of Pravastatin™ on AQP1 expression in
HUVECs cultured under static conditions. Pravastatin™ has no effect on AQP1 protein
expression in HUVECs cultured under static culture conditions after 24 and 48 hours of
culture (Fig. 13, Panels B, F, J, N, R; Fig. 14; p>0.05).
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Figure 13. Pravastatin does not affect AQP1 expression in HUVECs cultured under
static conditions.
Immunocytochemistry images of AQP1 (Green), F-Actin (Red), and the cell nuclei (Blue)
acquired at 20x magnification of HUVECs cultured under static conditions (A-T) without
Pravastatin™ (A-H, M-P) and with Pravastatin™ (I-L, Q-T) for 0 (A-D), 24 (E-L), and 48
hours (M-T). Scale Bar: 100 µm.
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Figure 14. Pravastatin™ does not affect AQP1 expression in HUVECs cultured under
static conditions.
Mean fluorescent intensities (A.U.) of AQP1 (Fig. 13, Panels F, J, N, and R) normalized
to Static 0 Hour Control (Fig. 13, Panel B) with standard error of mean. No significant
differences across conditions were observed (p>0.05).

Pravastatin™ did not affect PECAM-1 expression in HUVECs cultured under
static conditions for 24 and 48 hours (Fig 15. Panels B, F, J, N, R; Fig. 16; p>0.05).
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Figure 15. PECAM-1 expression remains constant in HUVECs cultured under static
conditions with Pravastatin™.
Immunocytochemistry images of PECAM-1 (Green), F-Actin (Red), and the cell nuclei
(Blue) acquired at 20x magnification of HUVECs cultured under static conditions (A-T)
without Pravastatin™ (A-H, M-P) and with Pravastatin™ (I-L, Q-T) for 0 (A-D), 24 (EL), and 48 hours (M-T). Scale Bar: 100 µm.
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Figure 16. PECAM-1 expression is not affected by Pravastatin™ under static
conditions.
Mean fluorescent intensities (A.U.) of PECAM-1 (Fig. 15, Panels F, J, N, and R)
normalized to Static 0 Hour Control (Fig. 15, Panel B) with standard error of mean. No
significant differences across conditions were observed (p>0.05).

After 24 hours (Fig. 17, Panels I-L) and 48 hours (Fig. 17, Panels Q-T) of static
culture with 5 µM Pravastatin™, BMPER expression is significantly increased relative to
Static 0 Hour Control (Fig. 17, Panel J and R vs. Panel B; p<0.05).
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Figure 17. BMPER expression is increased in HUVECs cultured under static
conditions with Pravastatin™.
Immunocytochemistry images of BMPER (Green), F-Actin (Red), and the cell nuclei
(Blue) acquired at 20x magnification of HUVECs cultured under static conditions (A-T)
without Pravastatin™ (A-H, M-P) and with Pravastatin™ (I-L, Q-T) for 0 (A-D), 24 (EL), and 48 hours (M-T). Scale Bar: 100 µm.
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Effect of Venous Shear Stress and 5 µM Pravastatin™ on HUVECs.
Pravastatin™ was added to HUVEC cultures under venous flow conditions to
assess the interaction of venous shear stress and Pravastatin™ on HUVECs. These
experiments were performed to understand combinatorial effects of venous shear stress
and Pravastatin™ on AQP1 expression.
With the administration of 5 µM Pravastatin™ and the application of venous
flow, the previously mentioned venous shear-dependent increase in AQP1 expression
was repressed relative to Static 0 Hour Control (Fig. 18, Panels A-D; Fig. 19, A and E).
After 24 hours of venous fluid shear stress with Pravastatin™ (Fig. 18, Panels I-L), no
venous shear-dependent increase in AQP1 expression was measured. AQP1 expression
after 24 hours of venous flow and exposure to Pravastatin™ (Fig. 18, Panel J) was
reduced by 27% relative to Static 0 Hour Control (Fig. 18, Panel B; Fig. 19, B and D;
p<0.05). AQP1 expression after 48 hours of venous flow and exposure to Pravastatin™
(Fig. 18, Panel R) was also reduced by 27% relative to Static 0 Hour Control (Fig. 18,
Panel B; Fig. 19, C and F; p<0.05). There was no significant difference measured
between AQP1 expression after 24 hours and 48 hours of venous flow with Pravastatin™
(Fig. 18, Panels J and R).
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Figure 18. Venous shear induction of AQP1 is suppressed by Pravastatin™.
Immunocytochemistry images of AQP1 (Green), F-Actin (Red), and the cell nuclei (Blue)
acquired at 20x magnification of HUVECs cultured under venous flow conditions (A-T)
without Pravastatin™ (A-H, M-P) and with Pravastatin™ (I-L, Q-T) for 0 (A-D), 24 (EL), and 48 hours (M-T). Venous flow was applied from left to right. Scale Bar: 100 µm.
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Figure 19. Pravastatin™ suppresses venous shear induction of AQP1.
Mean fluorescent intensities (A.U.) of AQP1 (Fig. 18, Panels F, J, N, and R) normalized
to Static 0 Hour Control (Fig. 18, Panel B) with standard error of mean. Significant
differences (*) were determined at p<0.05.

PECAM-1 expression remained constant in venous flow cultures exposed to 5µM
Pravastatin™ relative to Static 0 Hour Control conditions. After 24 hours or 48 hours of
venous flow culture with Pravastatin™ there was no significant alteration of PECAM-1
expression relative to Static 0 Hour Control conditions (Fig. 20, Panels J and R vs. Panel
B; p>0.05). PECAM-1 expression did not change under static or venous flow conditions
at 24 and 48 hours of culture with and without Pravastatin™, indicating that shear stress
and Pravastatin™ combined do not differentially regulate PECAM-1 expression or cause
endothelial cell differentiation (p>0.05).
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Figure 20. PECAM-1 expression is not affected by shear stress or Pravastatin™.
Immunocytochemistry images of PECAM-1 (Green), F-Actin (Red), and the cell nuclei
(Blue) acquired at 20x magnification of HUVECs cultured under static (A-D) and venous
flow conditions (E-T) without Pravastatin™ (A-H, M-P) and with Pravastatin™ (I-L, QT) for 0 (A-D), 24 (E-L), and 48 hours (M-T). Scale Bar: 100 µm.
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Figure 21. Shear stress and Pravastatin™ do not affect PECAM-1 expression.
Mean fluorescent intensities (A.U.) (Fig. 20, Panels F, J, N, and R) were normalized to
Static 0 Hour Control (Fig. 20, Panel B) with standard error of mean. No significant
differences across conditions were observed (p>0.05).

After 24 hours (Fig. 22, Panels I-L) and 48 hours (Fig. 22, Panels Q-T) of venous
culture with 5 µM Pravastatin™, BMPER expression is significantly increased relative to
Static 0 Hour Control (Fig. 22, Panel J and R vs. Panel B; p<0.05). There is no significant
difference when comparing BMPER expression after 24 and 48 hours under venous flow
with Pravastatin™ (Fig. 22, Panels J and R) or between venous flow and static culture
BMPER expression after 24 and 48 hours with Pravastatin™ (Fig. 17, Panels J and R;
p>0.05). BMPER expression is only detectable with conditions using Pravastatin™.
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Figure 22. Pravastatin™ induces BMPER expression independent of shear stress.
Immunocytochemistry images of BMPER (Green), F-Actin (Red), and the cell nuclei
(Blue) acquired at 20x magnification of HUVECs cultured under static conditions (A-T)
and venous flow conditions (E-T) without Pravastatin™ (A-H, M-P) and with
Pravastatin™ (I-L, Q-T) for 0 (A-D), 24 (E-L), and 48 hours (M-T). Scale Bar: 100 µm.
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2.5 Discussion
Fluid shear-stress dependent induction of AQP1 in vascular endothelial cells was
confirmed in vitro as expected from previous investigations regarding the fluid shearstress dependent regulation of AQPs, specifically AQP1 (24, 28). This might suggest a
universal effect of shear stress on regulating AQP expression in multiple different cell
types.
Specifically, in HUVECs this increase in overall abundance of AQP1 might serve
to facilitate increasing endothelial cell volume under shear stress conditions. As the
endothelial cells are exposed to an increase in fluid shear stress, the endothelial cells
begin to align parallel to the direction of flow and elongate in response to flow. Cells
elongating under flow conditions may result in cytosolic volume changes of the cell that
in turn cause a compensatory response of increased AQP1 expression to compensate for
an increased cytosolic volume (8). The increase in AQP1 under increasing shear stress
suggests a potential mechanosensory signaling network for regulating AQP1 protein
expression in HUVECs under shear stress.
Since the vascular endothelium and endothelial cells are constantly under fluid
shear-stress in vivo, the most physiologically relevant understanding of the role of
Pravastatin™ on AQP1 expression in HUVECs would have to be obtained using an in
vitro recapitulation of venous fluid shear stress. Under static conditions with
Pravastatin™, AQP1 expression is not affected (p>0.05). However, with Pravastatin™
and the application of venous fluid shear stress, Pravastatin™ appears to not only block
or prevent the shear-stress mediated induction of AQP1 in HUVECs but also further
reduces levels of AQP1 expression to levels 27% less than those of control static

P a g e | 55

conditions (p<0.05). This combinatorial regulation demonstrated by Pravastatin™ and
shear stress suggests a novel relationship between Pravastatin™, shear stress, and the
regulation of AQP1.
While statins primarily function to reduce levels of low-density lipoprotein
cholesterol, statins are suggested to have a cholesterol-independent cardioprotective
effect by reducing endothelial permeability and vascular inflammation through the
inhibition of Rho GTPases (3). Additionally, statins have been shown to regulate AQP1
protein expression by increasing the expression of Kruppel-like factor 2 (KLF2) (27).
KLF2 is the transcription factor implicated in increasing AQP1 mRNA transcription
under shear stress, and this factor is suggested as one of the cardioprotective targets of
statin drugs in protecting endothelial tissue from cardiovascular disease (27). While the
majority of commercially available statin drugs demonstrates an upregulatory effect on
KLF2, the hydrophilic statin Pravastatin™ does not have any effect on the expression of
KLF2 in HUVECs (27). Considering that Pravastatin™ does not have an effect on KLF2
expression, this might explain why Pravastatin™ actually decreases AQP1 expression in
HUVECs under shear stress in vitro. Pravastatin™ may serve a different and novel role in
HUVECs distinct from the roles of other statin drugs, and this particular role of
Pravastatin™ results in the ultimate regulation of AQP1. These results further
demonstrate the growing amount of knowledge regarding a possible cholesterolindependent function of statin drugs in regulating the expression of AQPs. In addition,
these results suggest a potential cardioprotective benefit of Pravastatin™, independent of
its cholesterol-lowering function, that is related to the regulation of AQP1 in vascular
endothelial cells.
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The expression of PECAM-1 and BMPER were not altered by venous fluid shear
stress (p>0.05). PECAM-1 functions as an extracellular cell adhesion molecule that
allows for endothelial cell-cell adherence. PECAM-1 is also important in the overall
mechanosensory complex in endothelial cells in response to mechanical stimuli,
specifically shear stress (5). PECAM-1 also has potent cell-signaling properties through
the downstream activation of proto-oncogene tyrosine-protein kinase Fyn (FYN) (14).
This FYN kinase can internally activate the vascular endothelial growth factor receptor 2
(VEGFR2) which is another kinase crucial in many cell-signaling pathways involved in
endothelial function and response to shear stress (2, 20). It is possible that the observed
increase in AQP1 expression under shear stress conditions might stem from PECAM-1
dependent cell-signaling in response to an increase in shear stress. The observed decrease
in AQP1 expression in HUVECs in vitro under shear stress conditions might stem from
Pravastatin™ interacting with downstream signaling components of the PECAM-1
mediated mechanosensory complex in endothelial cells. With this proposed mechanism,
Pravastatin™ could alter downstream effects of PECAM-1 dependent mechanosensation
in endothelial cells and might regulate the downstream expression of AQP1. While
Pravastatin™ did not have any observed effect on PECAM-1 expression in this
investigation, it is understood that another statin drug called Lovastatin™ decreases the
expression of PECAM-1 in endothelial cells (31). Pravastatin™ is already known to be
the only statin drug that does not interact with the KLF2 in endothelial cells. This might
suggest that Pravastatin™ functions through a different mechanism than Lovastatin™
and does not directly regulate PECAM-1 expression (27).
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BMPER functions as a ligand that directly interacts with the Bone Morphogenetic
Protein Receptors and may play a role in endothelial cell differentiation in vasculogenesis
(23). BMPER is induced by Pravastatin™ under static and venous shear stress conditions
(p<0.05). BMPER expression was not affected by changes in shear stress (p>0.05),
validating the use of BMPER as a shear stress-independent control for Pravastatin™
action in endothelial cells.
Since statin drugs such as Pravastatin™ are considered cardioprotective agents, it
is important to reconcile the advantageous function of Pravastatin™ with its ability to
suppress venous shear induced AQP1 expression in HUVECs. A common concern in the
pathophysiology of cardiovascular disease, such as intimal hyperplasia, is vascular
inflammation caused by an increase in endothelial permeability (32). When the
endothelial cell layer becomes more permeable, the smooth muscle layer located beneath
the endothelial layer can be exposed directly to the blood flowing through the vessel.
This new environment can cause adverse changes to the smooth muscle layer resulting in
vessel disease such as IH (6). In AQP1-null mutants, it has been discovered that
individuals deficient in AQP1 have a decreased vascular permeability in the vessels of
the pulmonary vasculature (19). While this investigation demonstrated that AQP1 is a
determinant of vascular permeability in the lungs, it is possible that AQP1 functions in
the vascular endothelium in a similar manner.
Aquaporin 1 might be responsible for increasing the vascular permeability that
results in vessel disease. As AQP1 protein expression increases in an environment of
venous flow, more water channels can function in the membrane to facilitate water
movement. With an increase in water flux, it is possible that endothelial cells could swell
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resulting in larger junctions between other endothelial cells. As these junctions increase
in size, the permeability of the endothelial cell layer as a whole could increase. This
increase in endothelial layer permeability could potentially result in downstream vessel
disease and IH. Since Pravastatin™ represses the expression of AQP1 under venous flow,
it is possible that the cardioprotective function of Pravastatin™ in lowering endothelial
permeability functions through suppressing AQP1 protein expression. As AQP1 protein
expression is repressed, the overall volume of water flux in the endothelial cells could
decrease causing the cells not to swell and the junctions between cells to remain smaller
and less permeable. This repression of AQP1 protein expression under venous flow
conditions by Pravastatin™ could demonstrate a novel mechanism of action for statin
drugs in reducing vascular permeability and inflammation.
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Chapter 3: Reflection
It was the summer of 2013. As a freshly-minted high school graduate and a future
Flyer, I was ready to embark on the next stage of my academic journey. With a recent
interest in the possibility of medical school after college, but with no idea what being a
“pre-medical” student might mean, I desperately needed consultation on how I was even
going to attempt to proceed with this ambition. As I returned home from a day of work as
a cashier at the local health foods grocery store, my father informed me that he had been
able to set up a meeting on campus for the following week for me to talk about selecting
a major. The meeting was to be with Dr. Carissa Krane, Professor of Biology, who was
then also the Associate Director of the University Honors Program. Little did I know that
that meeting would change my whole college career and indeed my entire life trajectory.
I arrived on campus that next week ready to meet with Dr. Krane. My father
escorted me to her office in the University Honors Program. As we walked into Alumni
Hall and made our way to Dr. Krane’s office, my father coached me on how properly to
introduce myself. I pretended to listen, but I was too anxious for the meeting to pay much
attention to what he was saying. When we arrived at the office, and with some measure of
his preparation and my inattentiveness to it, I nervously reached my hand out and said,
“Good afternoon Dr. Krane. It’s a pleasure to meet you.” That was a very interesting
meeting. Dr. Krane asked me a series of probing questions, not just about what interested
me but how I liked to think, what kinds of questions interested me, and what kind of
work gave me pleasure. At the time, I was between engineering and biology in my
thinking about a possible major. Yet from our wide-ranging conversation, Dr. Krane was
able to convince me that studying biology would be the most appropriate course of study
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for me. Soon afterward she also showed me her laboratory in the Science Center. I
remember meeting the members of the lab—Kyle McGrail, Connor Ratycz, and Mark
Hawk—and listening to them discuss their research. I found myself so amazed that
undergraduates were performing such complex research that I immediately began to
develop the idea that I too wanted to participate in research during my time at the
university. This proved to be good thinking, for as the first year began I soon came to
learn that to be a Type-A, high-achieving pre-medical student, I would have to get
involved in undergraduate research to improve my medical school application. So I
reached out to Dr. Krane to see if she would have an availability in her lab the summer
after freshman year. To my surprise and delight she had a position and I began work that
summer in her lab.
Lab work was all I really thought this engagement with Dr. Krane’s lab would
ever be in my life. I never would have imagined that over the course of the next four
years that work would take me to the opportunities of being an American Physiological
Society Undergraduate Research Fellow, a Goldwater Scholar, a graduating senior with
an honors thesis from Dr. Krane’s laboratory, and now an accepted student at a fullyfunded M.D./Ph.D. program at the University of Pittsburgh. Since I was given that
opportunity to join Dr. Krane’s laboratory, I have never looked back. Dr. Krane started
me on my college path and she provided the foundation for my opportunities here at UD
and into the future as I approach medical school and my anticipated career as a physician
scientist.
While I currently write in high regard of my experiences in Dr. Krane’s laboratory
and where those experiences have taken me, this journey has not been without its
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challenges. When I began my lab work, I was a naïve, introductory biology student who
only had a very general idea about going to medical school and no real knowledge of
what that really meant. I did not know what a physician really did except for what I had
seen by visiting my own pediatrician. All I knew was that I wanted to help people
suffering from diseases in some way, and this desire was personal. When I was a small
boy, my paternal grandfather died of a rare form of stomach cancer, and in my junior year
of high school, I lost my material grandmother to aggressive neurodegeneration related to
Parkinson’s disease. During those times, especially as my grandmother was dying, I felt
completely useless as I could only stand idly by as her disease manifested itself. Wanting
to learn and to be able to do something for others that I could not do for my grandfather
and grandmother was then my first (and only) inspiration for envisioning a career in
healthcare at the beginning of my college years.
I continued in the lab that summer after my first year of college, learning basic
laboratory techniques and becoming familiar with the literature of aquaporins and
cardiovascular biology, the eventual subjects of my Honors thesis. In this work, I
shadowed Kyle McGrail, a graduate student in the laboratory. I never really spent more
than a few hours a day in the lab, and I was actually rather bored by the monotony of the
tasks we performed. I was frustrated by how long it took to perform lab protocols and
how complex the material was. As I was having this negative reaction to laboratory work,
I became all the more confident that I wanted to be a physician while developing a
contrary certainty that I did not want to have a career in research. However, with a
potential letter of recommendation from Dr. Krane hanging in the balance, and that
requiring nothing short of my continuation in the lab, I persisted through the summer.
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Frankly, because I enjoyed working with and for Dr. Krane, and I admired her
knowledge and professionalism, that enjoyment and respect for her kept me going. That
was a good decision, for that next school year, my sophomore year, Dr. Krane
encouraged me to think about further work in the lab and worked with me to formulate an
application for the 2015 American Physiological Society (APS) Summer Undergraduate
Research Fellowship. If I were to get that fellowship, it would allow for me to stay on
campus during the following summer and continue my work in the laboratory. Even
though I had sworn off a career in the sciences the previous summer, I was excited to
apply for this fellowship and work on my own project. To my surprise and delight, I was
awarded the APS fellowship in late March, 2015. I never thought I would win this award,
and the boost of external validation that it provided greatly aided in creating within me a
new excitement around the idea of working in the laboratory again.
From Kyle, and through his remarkable generosity in sharing information, I
learned how to troubleshoot my experiments and enjoy my time—all those hours—in our
basement laboratory. Yet however much I learned from Kyle and benefitted from his
mentoring, I was also eager to come out from behind his shadow and begin working on
my own. The APS fellowship promised this possibility. I was not aware at the time that
the summer of 2015 would serve as the most challenging and formative period of my
growth in the laboratory.
The summer began quite differently from the previous summer. For one thing,
there was no more playing around with the pipettes and empty cell culture flasks. Since
the APS was paying me to undertake and further my own research, I needed to do some
work that I could present at the following year’s international Experimental Biology

P a g e | 67

meeting. With a fire set beneath me, I began pushing through the summer, immersing
myself deeper in the scientific literature and learning more about complicated laboratory
techniques. I began to appreciate how important were the skills of troubleshooting and
patience in the lab as I struggled for weeks with mastering effective RNA isolation. So
challenging was this that there were moments when I would break down in frustration at
the continual failures of my experiments. At times that summer I even wanted to quit lab
work forever, yet there was something inside me that wouldn’t let me do so. I don’t know
if that was my pride or my naivety, but I am thankful that I stuck with the lab throughout
that difficult summer and for the remainder of my undergraduate education.
I have found lab work to be difficult but immensely rewarding. There have been
moments when every experiment seemed to be failing and every draft of my Honors
thesis might be returned with a daunting amount of corrections and revisions to address.
Yet when I was interviewing at medical schools and was asked about my greatest
achievements, I often responded by talking about those very failures in my experiments
and the challenges I encountered in researching and writing my thesis. While I originally
thought that failures would be the death of my experiments and my enjoyment in the
laboratory, I soon discovered that I found excitement in troubleshooting experiments and
learning how to analyze my experiments and my ideas critically. I also discovered that I
often learned far more about research through my failures than through my successes. In
addition, through learning to fail and responding to and learning from those failures
methodically, I developed more of a “thick skin” against failure and criticism. The very
essence of scientific investigation and discovery is using experimental evidence and data
to support an argument. As with all arguments, there is always an opposition that will tell
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you that you are wrong and your thoughts are invalid. Before joining the Krane
laboratory, I tended to take all criticism as a personal criticism of my character, ability,
and intelligence. After an extended period of having to defend my research findings at
local, regional, and international conferences, not to mention in regular meetings with Dr.
Krane and in contacts with other faculty and students in the Department of Biology, I
came to realize that criticism and questioning make up the natural, indeed the essential
process of scientific research. Coming into this realization has made me a stronger
scientist and a more thoughtful and humble person.
Before I joined the lab, I could barely determine the difference between a
dependent and independent variable; now I feel confident in my ability to design and
implement an experiment from start to finish. The lab taught me how to think as an
individual and how to translate my abstract curiosities in science into tangible and
testable hypotheses. Above all, when I began in the lab, I had no interest in continuing
my course of research into a period of clinical training as a medical student. Now I stand
ready to matriculate into an M.D./Ph.D. program in which laboratory research will be a
mainstay of my education as well as a likely central feature of my future career.
In addition to my research and my scientific learning in and through the Krane
laboratory, the University of Dayton has provided me more than ample resources and
opportunities to fulfill my interest in clinical medicine and my related passion for
community service. As a biology major, I have been able to serve my community by
volunteering at the local free medical clinic, and this experience has expanded my
passion for and understanding of the health care profession. Working at that clinic also
taught me the value of providing medical care to underserved people.
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I am wholly satisfied that I chose biology as my major, and I am very grateful for
the experiences I have had in class and in the laboratory that have solidified and
expanded my interests in biology and medicine. Through these experiences in and
beyond the classroom, I have learned how to develop as a leader and how to serve as a
mentor to other students. Being so new to science myself just four years ago, I never
thought that I would develop such strong mentoring relationships with younger
undergraduates. I also could not have predicted how much I would enjoy teaching some
of the same skills and lessons I learned from others to young undergraduates and aspiring
researchers. I am proud of and very satisfied in the decision I made four years ago to
come to the University of Dayton and major in biology. I cannot imagine being at a better
institution than UD for learning biology, studying broadly across the whole of the liberal
arts and sciences, and developing into a budding scientist and, quite frankly, a better and
more thoughtful human being.

